All Updates

All Updates

icon
Filter
Partnerships
Biolojic Design signs AI deal with Merck KGaA for cancer and immunology treatments
AI Drug Discovery
Jun 3, 2024
This week:
Funding
Lhyfe receives EUR 11 million grant from Klimatklivet for green hydrogen project in Sweden
Hydrogen Economy
Yesterday
Product updates
XRAI Glass launches AR One glasses at USD 1449 for hearing-impaired individuals
Extended Reality
Yesterday
Funding
VR therapy platform CUREosity raises EUR 3.8 million in funding to expand market presence
Extended Reality
Yesterday
Last week:
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Decentralized Finance (DeFi)
Jun 22, 2024
Product updates
Coinbase updates mobile wallet to add decentralized app browser
Web3 Ecosystem
Jun 22, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Data Infrastructure & Analytics
Jun 21, 2024
M&A
OpenAI acquires Rockset to power retrieval infrastructure
Foundation Models
Jun 21, 2024
Partnerships
Product updates
Anthropic releases Claude 3.5 Sonnet, the first model in the 3.5 series
Foundation Models
Jun 21, 2024
Funding
Paramount Planet Product raises USD 1 million in federal grant funding to support commercialization
Bio-based Materials
Jun 21, 2024
Regulation/policy
Apple delays launch of Apple Intelligence features in EU citing regulatory concerns
Generative AI Applications
Jun 21, 2024
AI Drug Discovery

AI Drug Discovery

Jun 3, 2024

Biolojic Design signs AI deal with Merck KGaA for cancer and immunology treatments

Partnerships

  • Israel-based AI biotech company Biolojic Design has collaborated with Merck KGaA to design therapeutic antibodies to treat cancer and immunological disorders. As part of the agreement, Biolojic Design will receive a low double-digit million Euro upfront payment, milestone payments amounting to EUR 346 million (USD 376 million), and royalties on sales.

  • The partnership will leverage Biolojic’s AI capabilities to create potential antibody-based therapies, including antibody-drug conjugates (ADCs) useful for cancer treatment. 

  • Biolojic Design specializes in the computational design of functional antibodies. Leveraging AI, it transforms antibodies into intelligent medicinal solutions targeting specific epitopes to perform novel biological functions. The company's platform produces mono-specific and multi-specific antibodies to treat autoimmune diseases and cancers by precisely modulating biological pathways.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.